The biopharma firm reports a Q3 GAAP loss of $0.09 per share and cash reserves of $3.2 million as of March 31, 2026.
NanoViricides reported a GAAP loss of $0.09 per share for the third quarter, reflecting ongoing research and development expenses. The company’s cash position remains tight, with $3.2 million in cash and equivalents as of March 31, 2026.
The loss aligns with the firm’s historical trend of negative earnings as it advances clinical-stage antiviral therapies. Prior quarters showed similar losses, with no revenue-generating products yet on the market.
Management stated the current cash balance is expected to support operations, though further funding may be required for long-term development.